4.6 Review

ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-Analysis Including Results from the CAN-BIND-1 Study

Journal

CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 114, Issue 1, Pages 88-117

Publisher

WILEY
DOI: 10.1002/cpt.2854

Keywords

-

Ask authors/readers for more resources

In this study, the association between six ABCB1 single-nucleotide polymorphisms (SNPs) and antidepressant treatment outcomes was investigated through a systematic review and meta-analysis. No significant association was found between ABCB1 SNPs and antidepressant treatment outcomes in the CAN-BIND-1 sample. However, a significant association between rs1128503 and treatment response was observed in the meta-analysis. These findings provide limited evidence for the implementation of ABCB1 genotyping to inform antidepressant treatment.
The P-glycoprotein efflux pump, encoded by the ABCB1 gene, has been shown to alter concentrations of various antidepressants in the brain. In this study, we conducted a systematic review and meta-analysis to investigate the association between six ABCB1 single-nucleotide polymorphisms (SNPs; rs1045642, rs2032582, rs1128503, rs2032583, rs2235015, and rs2235040) and antidepressant treatment outcomes in individuals with major depressive disorder (MDD), including new data from the Canadian Biomarker and Integration Network for Depression (CAN-BIND-1) cohort. For the CAN-BIND-1 sample, we applied regression models to investigate the association between ABCB1 SNPs and antidepressant treatment response, remission, tolerability, and antidepressant serum levels. For the meta-analysis, we systematically summarized pharmacogenetic evidence of the association between ABCB1 SNPs and antidepressant treatment outcomes. Studies were included in the meta-analysis if they investigated at least one ABCB1 SNP in individuals with MDD treated with at least one antidepressant. We did not find a significant association between ABCB1 SNPs and antidepressant treatment outcomes in the CAN-BIND-1 sample. A total of 39 studies were included in the systematic review. In the meta-analysis, we observed a significant association between rs1128503 and treatment response (T vs. C-allele, odds ratio = 1.30, 95% confidence interval = 1.15-1.48, P value (adjusted) = 0.024, n = 2,526). We did not find associations among the six SNPs and treatment remission nor tolerability. Our findings provide limited evidence for an association between common ABCB1 SNPs and antidepressant outcomes, which do not support the implementation of ABCB1 genotyping to inform antidepressant treatment at this time. Future research, especially on rs1128503, is recommended.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Neurosciences

Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study

Prabhjot Dhami, Lena C. Quilty, Benjamin Schwartzmann, Rudolf Uher, Timothy A. Allen, Stefan Kloiber, Raymond W. Lam, Glenda MacQueen, Benicio N. Frey, Roumen Milev, Daniel J. Mueller, Stephen C. Strother, Pierre Blier, Claudio N. Soares, Sagar V. Parikh, Gustavo Turecki, Jane A. Foster, Susan Rotzinger, Sidney H. Kennedy, Faranak Farzan

Summary: The neurobiological correlates of response inhibition can predict the response of patients with major depressive disorder (MDD) to pharmacological and cognitive behavioral therapy treatment. The integrity of response inhibition may be crucial for the success of treatment for MDD. Electrophysiological correlates of response inhibition may serve as a general prognostic marker for treatment response in MDD.

BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING (2023)

Review Clinical Neurology

Early optimized pharmacological treatment in patients with depression and chronic pain

Oloruntoba J. Oluboka, Martin A. Katzman, Jeffrey Habert, Atul Khullar, Margaret A. Oakander, Diane McIntosh, Roger S. McIntyre, Claudio N. Soares, Raymond W. Lam, Larry J. Klassen, Robert Tanguay

Summary: Major depressive disorder (MDD) is the leading cause of disability worldwide, and comorbid chronic pain exacerbates disability and healthcare burden. Managing patients with both MDD and chronic pain can be challenging due to shared underlying mechanisms. Current treatment guidelines address comorbid conditions such as anxiety and cardiovascular disease, but not chronic pain. Rapidly and aggressively treating depression according to guideline recommendations, using antidepressants with analgesic properties, while also addressing pain, is recommended based on clinical experience.

CNS SPECTRUMS (2023)

Article Endocrinology & Metabolism

Factors Associated With Initiation of Antidepressant Medication in Adults With Type 1 and Type 2 Diabetes: A Primary Care Retrospective Cohort Study in Ontario, Canada

Osnat C. Melamed, Sumeet Kalia, Rahim Moineddin, Michelle Greiver, Stefan Kloiber, Benoit H. Mulsant, Peter Selby, Braden G. O'Neill

Summary: This study aims to identify demographic, socioeconomic and medical factors associated with the initiation of antidepressant medication in adult patients with diabetes. The study found that younger age, female gender, insulin treatment, and polypharmacy were associated with higher odds of antidepressant initiation. Patients also had increased visits to primary care after antidepressant initiation.

CANADIAN JOURNAL OF DIABETES (2023)

Article Pharmacology & Pharmacy

Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype

Roseann S. Gammal, Munir Pirmohamed, Andrew A. Somogyi, Sarah A. Morris, Christine M. Formea, Amanda L. Elchynski, Kazeem A. Oshikoya, Howard L. McLeod, Cyrine E. Haidar, Michelle Whirl-Carrillo, Teri E. Klein, Kelly E. Caudle, Mary Relling

Summary: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with the development of acute hemolytic anemia in the presence of oxidative stress. This guideline provides information on using G6PD genotype for diagnosing G6PD deficiency and categorizes medications based on their risk level in individuals with G6PD deficiency. High-risk medications should be avoided, medium-risk medications should be used with caution, and low-risk medications can be used without considering the G6PD phenotype.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Psychology, Clinical

Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 report

Mehri Sajjadian, Rudolf Uher, Keith Ho, Stefanie Hassel, Roumen Milev, Benicio N. Frey, Faranak Farzan, Pierre Blier, Jane A. Foster, Sagar Parikh, Daniel J. Mueller, Susan Rotzinger, Claudio N. Soares, Gustavo Turecki, Valerie H. Taylor, Raymond W. Lam, Stephen C. Strother, Sidney H. Kennedy

Summary: Predicting treatment outcomes for major depressive disorder can be improved by combining clinical, neuroimaging, and molecular data. Early measurement during treatment can increase precision, but adding more features does not necessarily enhance prediction accuracy.

PSYCHOLOGICAL MEDICINE (2023)

Article Psychiatry

AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale

Cynthia H. Y. Fu, Guray Erus, Yong Fan, Mathilde Antoniades, Danilo Arnone, Stephen R. Arnott, Taolin Chen, Ki Sueng Choi, Cherise Chin Fatt, Benicio N. Frey, Vibe G. Frokjaer, Melanie Ganz, Jose Garcia, Beata R. Godlewska, Stefanie Hassel, Keith Ho, Andrew M. McIntosh, Kun Qin, Susan Rotzinger, Matthew D. Sacchet, Jonathan Savitz, Haochang Shou, Ashish Singh, Aleks Stolicyn, Irina Strigo, Stephen C. Strother, Duygu Tosun, Teresa A. Victor, Dongtao Wei, Toby Wise, Rachel D. Woodham, Roland Zahn, Ian M. Anderson, J. F. William Deakin, Boadie W. Dunlop, Rebecca Elliott, Qiyong Gong, Ian H. Gotlib, Catherine J. Harmer, Sidney H. Kennedy, Gitte M. Knudsen, Helen S. Mayberg, Martin P. Paulus, Jiang Qiu, Madhukar H. Trivedi, Heather C. Whalley, Chao-Gan Yan, Allan H. Young, Christos Davatzikos

Summary: In this study, a consortium called "COORDINATE-MDD" was established to define patterns of brain alteration in major depressive disorder (MDD) using neuroanatomical and neurofunctional heterogeneity as dimensions. By harmonizing imaging data and using machine learning methods, the project aims to predict treatment response at the individual level. International datasets from various MDD populations are being shared, and novel predictors of treatment response are being identified and validated externally.

BMC PSYCHIATRY (2023)

Article Psychiatry

Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study

Farhana Islam, Leen Magarbeh, Samar S. M. Elsheikh, Stefan Kloiber, Caroline W. Espinola, Venkat Bhat, Benicio N. Frey, Roumen Milev, Claudio N. Soares, Sagar V. Parikh, Franca Placenza, Stefanie Hassel, Valerie H. Taylor, Francesco Leri, Pierre Blier, Rudolf Uher, Faranak Farzan, Raymond W. Lam, Gustavo Turecki, Jane A. Foster, Susan Rotzinger, Sidney H. Kennedy, Daniel J. Mueller

Summary: Treatment-emergent sexual dysfunction is a common issue in individuals with major depressive disorder on antidepressants. This study found that polymorphisms in genes encoding drug-metabolizing enzymes and the transmembrane efflux pump were associated with changes in sexual function and satisfaction. Specifically, CYP2C19 metabolizer phenotypes were linked to changes in sexual arousal, and higher concentrations of the escitalopram metabolite, S-desmethylcitalopram, were associated with a decline in sexual function and satisfaction in females.

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2023)

Meeting Abstract Neurosciences

Genetic Polymorphism of Brain-Derived Neurotrophic Factor is Related to Antidepressant Efficacy and Treatment-Induced Hippocampal Plasticity in Patients With Major Depressive Disorder: CAN-BIND-1 Study

Nikita Nogovitsyn, Laura Fiori, Sakina J. Rizvi, Amanda K. Ceniti, Pedro Ballester, Jane A. Foster, Katharine Dunlop, Keith Ho, Stefanie Hassel, Roumen V. Milev, Claudio N. Soares, Stephen C. Strother, Stephen R. Arnott, Raymond W. Lam, Rudolf Uher, Sagar V. Parikh, Faranak Farzan, Valerie H. Taylor, Glenda MacQueen, Daniel J. Mueller, Gustavo Turecki, Susan Rotzinger, Benicio N. Frey, Sidney H. Kennedy

BIOLOGICAL PSYCHIATRY (2023)

Article Psychiatry

Gray matter volume drives the brain age gap in schizophrenia: a SHAP study

Pedro L. L. Ballester, Jee Su Suh, Natalie C. W. Ho, Liangbing Liang, Stefanie C. Hassel, Stephen C. C. Strother, Stephen R. R. Arnott, Luciano Minuzzi, Roberto B. B. Sassi, Raymond W. W. Lam, Roumen Milev, Daniel J. J. Mueller, Valerie H. H. Taylor, Sidney H. H. Kennedy, James P. P. Reilly, Lena Palaniyappan, Katharine Dunlop, Benicio N. N. Frey

Summary: Neuroimaging-based brain age is a biomarker generated through machine learning predictions, showing a higher brain age in individuals with schizophrenia. The specific factors driving these predictions and their biological interpretations are still not well understood.

SCHIZOPHRENIA (2023)

Article Psychiatry

Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia

Helena K. Kim, Vanessa F. Gonsalves, Muhammad I. Husain, Daniel J. Mueller, Benoit H. Mulsant, Gwyneth Zai, Stefan Kloiber

Summary: The study investigates the association between the endocannabinoid system (ECS) and multiple mental disorders using a cross-disorder genome-wide association study (GWAS) meta-analysis. The findings suggest that the ECS may be a shared pathway in mental disorders. Nine single nucleotide polymorphisms (SNPs) were identified as significantly associated with a change in risk of having a mental disorder, with the DAGLA gene showing the strongest association.

PSYCHIATRY RESEARCH (2023)

No Data Available